2021 DORIS definition of remission in SLE: final recommendations from an international task force.
Authors
Bertsias, George
Isenberg, David
Rahman, Anisur
Voskuyl, Alexandre
Cervera, Ricard
Costedoat-Chalumeau, Nathalie
Gordon, Caroline
Mosca, Marta
Schneider, Matthias
Ward, Michael M
Alarcon, Graciela
Askenase, Anka
Bootsma, Hendrika
Clarke, Ann Elaine
Coney, Cindy
Czirják, László
Faria, Raquel
Fischer, Rebecca
Fritsch-Stork, Ruth
Inanc, Murat
Jayne, David
Kuhn, Annegret
van Leeuw, Bernadette
Limper, Maarten
Mariette, Xavier
Navarra, Sandra
Nikpour, Mandana
Olesinska, Marzena Helena
Pons-Estel, Guillermo
Romero-Diaz, Juanita
Rubio, Blanca
Schoenfeld, Yehuda
Bonfá, Eloisa
Smolen, Josef
Tincani, Angela
Vasconcelos, Carlos
Voss, Anne
Zakharhova, Elena
Publication Date
2021-11Journal Title
Lupus Sci Med
ISSN
2053-8790
Publisher
BMJ
Volume
8
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
van Vollenhoven, R. F., Bertsias, G., Doria, A., Isenberg, D., Morand, E., Petri, M. A., Pons-Estel, B. A., et al. (2021). 2021 DORIS definition of remission in SLE: final recommendations from an international task force.. Lupus Sci Med, 8 (1) https://doi.org/10.1136/lupus-2021-000538
Abstract
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
Keywords
Epidemiology and outcomes, 1506, 2257, lupus erythematosus, systemic, outcome assessment, healthcare, therapeutics
Sponsorship
UCB Pharma (n/a)
GlaxoSmithKline (n/a)
Identifiers
lupus-2021-000538
External DOI: https://doi.org/10.1136/lupus-2021-000538
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334001
Rights
Licence:
http://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk